Since triple-negative breast cancer (TNBC) was first defined over a decade ago, increasing
studies have focused on its genetic and molecular characteristics. Patients diagnosed with …

Early assessment of response to neoadjuvant chemotherapy (NAC) might be helpful in
avoiding the toxicity of ineffective chemotherapy and allowing refinement of treatment. We …

Purpose To provide an organized, international, state-of-the-art, and multidisciplinary
guideline, led by experts of two nuclear medicine societies (EANM and SNMMI) and …

Purpose To determine if pretreatment [18F] FDG PET/CT could contribute to predicting
complete pathological complete response (pCR) in patients with early-stage triple-negative …

Cancer-derived extracellular vesicles (EVs) contain various cancer-associated molecules,
such as mutated or overexpressed oncoproteins, glycoproteins, mRNAs, various non-coding …

Ideally, neoadjuvant chemotherapy (NAC) assessment should predict pathologic complete
response (pCR), a surrogate clinical endpoint for 5-year survival, as early as possible during …

Epidermal growth factor receptor (EGFR) is a transmembrane tyrosine kinase receptor,
which is overexpressed in many types of cancer. The use of EGFR-targeting monoclonal …

Patients with triple-negative breast cancer (TNBC) have poor outcome when pathologic
complete response (pCR) is not reached after neoadjuvant chemotherapy. Early prediction …

The role of fludeoxyglucose (FDG) PET in the management of patients with breast cancer
(BC) is evolving. Combined PET and computed tomography (CT) systems (PET/CT) have …

OBJECTIVE. Precision medicine in oncology aims to individualize the patient's treatment
and management regimen according to the accurate assessment of diagnosis, risk of …